



30th October, 2026

The Secretary
BSE Ltd.
Corporate Relationship Dept.,
14th floor, P. J. Tower,
Dalal Street, Fort
Mumbai - 400 001
Stock Code – 500331

The Secretary
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex,
Bandra (E),
Mumbai - 400 051
Stock Code - PIDILITIND

Dear Sir,

Sub: Newspaper Publication – Financial Results

Please find enclosed clippings of the “Extract of Financial Results for the quarter and six months ended 30th September, 2026” published on 30th October, 2026 in Business Standard (all editions) in English and Sakal (Mumbai Edition).

This is for your information and records.

Thanking You,

Yours faithfully,
For Pidilite Industries Limited

MANISHA
RAKESH
SHETTY

Digitally signed by
MANISHA RAKESH
SHETTY
Date: 2026.10.30
14:06:14 +05'30'

Manisha Shetty
Company Secretary

Encl as above

Regd. Office
Regent Chambers, 7th Floor
Jamnalal Bajaj Marg
208 Nariman Point
Mumbai 400 021

Pidilite Industries Limited
Corporate Office
Ramkrishna Mandir Road
Andheri - E, Mumbai 400059, India
T + 91 22 2835 7000
2835 7952 / 2835 7365
F +91 22 2830 4482
www.pidilite.com
CIN: L24100MH1969PLC014336

EUROPE GIVES FILLIP DESPITE US FALL

Pharma exports grow 5% in first half of FY27

SANKET KOUL
New Delhi, 29 October

Pharmaceutical exports grew 4.9 per cent year-on-year (Y-o-Y) to \$16.14 billion during the first half of 2026-27 (H1FY27), on higher dealings with non-United States (US) markets, even as shipments to the US fell.

While the Pharmaceutical Export Promotion Council of India (Pharmexcil) did not share data for US markets, it claimed that export shipments moderated during the period.

Exports to Europe increased 9.66 per cent to \$3.29 billion, accounting for over one-fifth of total pharmaceutical exports in H1FY27, with Germany, the Netherlands and France recording strong growth.

“The gains across these markets highlight the opportunities for Indian exporters to deepen their engagement with Europe,” Pharmexcil stated.

Similarly, shipments to the Association of South East Asian Nations (ASEAN) grew 21.54 per cent, while Latin

DRUG FORMULATIONS AND BIOLOGICALS REMAINED THE LARGEST EXPORT CATEGORY, ACCOUNTING FOR 73.84% OF TOTAL SHIPMENTS, WITH ITS SHARE GROWING BY 3.81%



America and the Caribbean recorded 16.58 per cent growth and Africa grew 6.48 per cent.

“These gains also helped sustain India’s overall pharma export growth, even as shipments to the US moderated, highlighting the importance of a geographically diversified export presence,” Pharmexcil stated.

The geographical gains were matched by growth in key product categories over the same period. Drug formulations and biologicals remained the largest export category, accounting for 73.84 per cent of total shipments, with its share growing by 3.81 per cent over the previous corresponding period.

“Bulk drugs and drug intermediates grew 12.07 per cent, while surgical exports increased 9.53 per cent. The product mix underscores the range of medicines and healthcare products supplied by Indian pharmaceutical exporters,” Pharmexcil said.

Pharmexcil Chairman Namit Joshi added that the next phase of India’s pharma export growth should focus on moving up the value chain, where Indian companies are not just suppliers but active partners in pharmaceutical innovation.

“This will require greater investment in research and development, technology transfer and co-development of complex generics, biosimilars and specialised therapies,” he said.

Pharma and healthcare deals surge 23% in Q3

India’s pharmaceutical and healthcare sector recorded 87 transactions valued at \$4.3 billion in the third quarter of 2026 (July to September period), according to a report by Grant Thornton Bharat.

This is a 23 per cent rise in volumes and a 69 per cent drop in values compared to Q2 2025 (April to July), which saw 65 deals in the sector worth \$13.9 million. The drop in deal value was attributable to the \$11.75 billion Sun Pharma-Organon transaction in Q2 2026, rather than a slowdown in underlying activity.

Of the \$4.3 billion in deals recorded this quarter, private deals such as mergers and acquisitions (M&A) and private equity (PE) activity accounted for around \$2.3 billion across 81 transactions. While M&A activity in the healthcare and pharmaceutical sector saw a marginal 6 per cent rise in volumes compared with the previous quarter, the PE landscape recorded a 69 per cent rise in volumes.

Public market fundraising also strengthened, with four Initial Public Offerings raising \$1.27 billion and two qualified institutional placements raising \$162 million.

SANKET KOUL

Govt, Volkswagen clash in court over record \$1.2 billion tax dispute

REUTERS
29 October

India defended its record \$1.2 billion tax demand against Volkswagen (VW) in a Mumbai court on Thursday, saying the German company never provided required information in time, while the car-maker argued the demand came years too late.



THE CASE WILL NEXT BE HEARD ON TUESDAY

India has since 2024 alleged Volkswagen undervalued auto imports for years and paid below the full tariff rates. The case is a major overhang for the carmaker, which is currently in talks with India’s JSW to sell a stake in its India operations.

Volkswagen, which has a roughly 2 per cent market share in the world’s third biggest car market, denies the allegations, and has previously said the case is a matter of “life and death” for its India business, and is “impossibly enormous”.

The dispute over India’s biggest ever import tax demand restarted last week after the high court in Mumbai said in August it would hear Volkswagen challenge afresh as judges failed to pass a ruling in time.

On Thursday, Volkswagen’s counsel Arvind Datar told the judges India tax authorities could not have gone back 12 years in scrutinising its imports as Indian law allows officials to only go back up to the past five years.

Additional Solicitor General N Venkataraman, one of the government’s top lawyers, said Volkswagen didn’t provide the information sought in time, adding that no other automaker in the country which imports parts had indulged in such misconduct.

“No other company has challenged this,” he said.

Volkswagen is accused of declaring its imports as individual auto parts and paid 5 per cent to 15 per cent tariff, though it was bringing in “almost the entire car” in unassembled condition for which it should have paid a 30-35 per cent tax rate, India has alleged.

The probe has spooked foreign investors, as lengthy import tariff and tax cases have long been a sore point for companies and affected companies like Samsung and LG. The case will next be heard on Tuesday.



GREENPLY INDUSTRIES LIMITED

Registered Office: “Madgul Lounge”, 6th Floor, 23 Chetla Central Road, Kolkata - 700 027

Corporate Identification Number: L20211WB1990PLC268743

Phone: (033) 3051-5000, E-mail: Investors@greenply.com, Website: www.greenply.com

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

The Board of Directors of Greenply Industries Limited (“the Company”) at its meeting held on October 29, 2026 has approved the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforementioned financial results along with the limited review reports of the Statutory Auditors have been posted on the Company’s website at <https://www.greenply.com/investors> and can be accessed by scanning the QR code.



Date : October 29, 2026
Place : Kolkata

By Order of the Board
For GREENPLY INDUSTRIES LIMITED

Sd/-
Sanidhya Mittal
Joint Managing Director
[DIN: 06579890]

Note: The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pidilite Industries Limited



Extract of Financial Results for the Quarter and Six Months ended 30.09.2026

(₹ In crores)

Sr No.	Particulars	Standalone					Consolidated				
		Quarter ended		Six months ended		Year ended	Quarter ended		Six months ended		Year ended
		30.09.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	4124.26	3355.82	8467.91	6919.30	13766.10	4362.18	3604.60	9005.73	7443.41	14867.01
2	Net Profit for the period (before tax and Exceptional items)	842.24	779.75	1961.76	1659.14	3201.89	834.23	787.31	2011.81	1703.78	3333.88
3	Net Profit for the period before tax (after Exceptional items)	842.24	779.75	1961.76	1659.14	3194.34	834.23	787.31	2026.22	1703.78	3320.17
4	Net Profit for the period after tax (after Exceptional items)	647.00	585.90	1476.87	1235.70	2384.30	626.46	584.60	1509.97	1262.73	2470.72
5	Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	646.88	583.07	1476.63	1230.04	2383.82	634.44	596.88	1517.04	1274.42	2494.95
6	Equity Share Capital	101.85	101.77	101.85	101.77	101.78	101.85	101.77	101.85	101.77	101.78
7	Reserves excluding Revaluation Reserve (as shown in the Audited Balance Sheet of the previous year)					10563.59					10730.39
8	Earnings Per Share (of ₹ 1/- each)* -										
	Basic:	@ 6.36	@ 5.76	@ 14.51	@ 12.15	23.43	@ 6.04	@ 5.69	@ 14.61	@ 12.30	24.07
	Diluted:	@ 6.35	@ 5.74	@ 14.48	@ 12.12	23.37	@ 6.03	@ 5.68	@ 14.58	@ 12.27	24.01

@ For the period only and not annualised.

Note:

- The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial results were reviewed by the Audit Committe and approved by the Board of Directors at their respective meetings held on 28th October, 2026. The full format of the Unaudited Financial Results are available on the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and on Company’s website www.pidilite.com.



Place : Mumbai
Date : 28th October, 2026

SUDHANSHU VATS
Managing Director

Regd. Office: 7th Floor, Regent Chambers, Jamnalal Bajaj Marg, 208, Nariman Point, Mumbai - 400 021.

Tel.: 91 22 6769 7000

Email: investor.relations@pidilite.co.in

www.pidilite.com

CIN: L24100MH1969PLC014336



